ONE-WAYDated event · through FY2025-H1

Obtaining approval for a high-dose methylcobalamin formulation for ALS

A program to pursue orphan drug designation, regulatory approval application, and approval in Japan for a high-dose methylcobalamin formulation (E0302), based on the results of an investigator-initiated Phase III trial aimed at slowing the progression of ALS.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2023-Q1 →Last written FY2025-H1

Directionhelps1 helps · 0 hurts · 0 flat